Provided by Tiger Trade Technology Pte. Ltd.

Oric Pharmaceuticals Inc.

13.13
+0.24001.86%
Post-market: 13.280.1500+1.14%19:30 EDT
Volume:1.55M
Turnover:20.28M
Market Cap:1.36B
PE:-9.72
High:13.53
Open:12.97
Low:12.83
Close:12.89
52wk High:14.93
52wk Low:7.23
Shares:103.52M
Float Shares:88.69M
Volume Ratio:1.63
T/O Rate:1.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3513
EPS(LYR):-1.4747
ROE:-39.80%
ROA:-25.97%
PB:3.57
PE(LYR):-8.90

Loading ...

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire
·
3 hours ago

Oric Pharma CFO Dominic Piscitelli Disposes of 77,000 Common Shares Worth $1.05 Million

Reuters
·
Aug 29

Pharscin Pharmaceutical Receives Clinical Trial Approval for Glaucoma Eye Drop Candidate

Stock News
·
Aug 13

Oric Pharmaceuticals is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 10

Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Janux Therapeutics Inc (JANX) and Entrada Therapeutics Inc (TRDA)

TIPRANKS
·
Aug 10

Oric Pharma Grants 125,400 Stock Options, 20,550 RSUs to Five New Employees

Reuters
·
Aug 08

Oric Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 08

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 08

Evercore ISI Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)

TIPRANKS
·
Aug 04

Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), ClearPoint Neuro (CLPT) and Keros Therapeutics (KROS)

TIPRANKS
·
Aug 04

ORIC Pharmaceuticals: Buy Rating Reaffirmed with Unchanged $25 Price Target on Multiple Oncology Catalysts and mCRPC Upside

TIPRANKS
·
Aug 04

Oric Pharmaceuticals: Q2 Net Loss Per Share $0.38

THOMSON REUTERS
·
Aug 04

ORIC Pharmaceuticals Q2 EPS $(0.38) Misses $(0.36) Estimate

Benzinga Earnings
·
Aug 04

Oric Pharmaceuticals Initiates Himalayas-1 Phase 3 Trial of Rinzimetostat Plus Darolutamide in mCRPC

Reuters
·
Aug 04

ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates

GlobeNewswire
·
Aug 04

Oric Pharmaceuticals Expands 2022 Inducement Equity Plan Share Pool by 1,100,000 Shares

Reuters
·
Jul 31

Oric Pharma Director Richard A. Heyman Disposes of 13,100 Common Shares Worth $157,462.00

Reuters
·
Jul 29

ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026

GlobeNewswire
·
Jul 20

Corrected-oric Pharmaceuticals: ‍entered Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Darolutamide for Himalayas-1 (not 'oric Pharmaceuticals Inc: Proposed Deal For')

THOMSON REUTERS
·
Jul 15

Oric Pharmaceuticals Signs Trial Collaboration with Bayer for Nubeqa Supply in Phase 3 Prostate Cancer Study

Reuters
·
Jul 15